BCRX reports delay in flu program

BioCryst (BCRX) partner R.W. Johnson Pharmaceutical Research Institute, a subsidiary of Johnson & Johnson (JNJ), said it will not begin a North American Phase III trial of the companies' RWJ-270201 or...